Human Immunodeficiency Virus Market - Forecast(2024 - 2030)

Human Immunodeficiency Virus Market Overview

Human Immunodeficiency Virus Market size is estimated to reach $3.5 billion by 2027, growing at a CAGR of 8.9% during the forecast period 2022-2027. Human Immunodeficiency is a sexually communicated disease STI which leads to hazardous sickness like AIDS (= acquired immunodeficiency syndrome). It attacks and cripples the cell's capacity to fight maladies. HIV belongs to a special class of retroviruses which is termed lentiviruses. Lentiviruses comprise of viruses like EIAV (=equine infectious anemia virus), FIV (= feline immunodeficiency virus), SIV (= simian immunodeficiency virus), and HIV. Involving into an unprotected sexual course, oral sexual activities, interaction with Disease-ridden blood, genetic transfer from mother to child are some common causes in the prevalence of HIV. Though there is not a sure-fire system to cure such infection. Though, its evolution can be controlled with some remedial drugs and procedures, ART (=antiretroviral therapy) is a preeminent therapy that enhances the CD-4 cells (= T-cells that maintain immunity to fight ailments) count in the body. Intensification in steps and initiatives by the government to enlarge consciousness among people are set to drive the growth of the Human Immunodeficiency Virus Industry for the period 2022-2027.

Report Coverage:

The report: “Human Immunodeficiency Virus Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Human Immunodeficiency Virus Market.

By Medication: NRTIs, NNRTIs, HIV integrase strand transfer inhibitors entry and fusion inhibitors, and PIs.
By Diagnostic tests: NAT (=nucleic acid test), CD-4, Antibody test, Viral identification, HIV screening test, etc.
By Diagnosing Bodies: Hospitals, Research and Diagnostic laboratories, and Blood banks, etc.
By Geography: North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, and Rest of South America) and Rest of World (the Middle East and Africa).

Key Takeaways:

• Geographically, the North America Human Immunodeficiency Virus Market accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the habitation of world-class laboratories for research and diagnosis.
• The upsurge in the figure of people falsified with HIV is thrusting the human immunodeficiency syndrome. However, a crippled supply chain of necessary APIs, drugs, and tools required in the diagnosis process due to trade restrictions posed by COVID-19 is one of the major factors that are said to reduce the growth of the HIV Market.
• Detailed analysis on the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Human Immunodeficiency Virus Market report.
  
  

  Human Immunodeficiency Virus Market- Geography (%) for 2021

  

Human Immunodeficiency Virus Market Segment Analysis - By Medication

The Human Immunodeficiency Virus Market based on the medication type can be further segmented into NRTIs (= nucleoside reverse transcriptase inhibitors), multi-class combination drugs (= odefsey, stribild, atripla, symtuza, prezista, etc.), NNRTIs (= non-nucleoside transcriptase inhibitors), HIV integrase strand transfer inhibitors (= isentress), entry and fusion inhibitors, PIs (= protease inhibitors). The Multiclass combination drugs segment held the largest share in 2021 owing to the factors such as extensive usage of such single-tablet regimens into HIV treatments like ART (= antiretroviral therapy). Within the US, approximately 1.2 million people have the said condition, of which 13% are not aware.

Moreover, the multiclass combination segment is estimated to be the fastest-growing segment with a CAGR of 9.5% over the period 2022-2027. This growth is owing to the supplementary efficacy of such drugs while combined with curative therapies, reimbursements like improving the immunity of patients, intensification the CD-4 count, also known as T or white blood cells.

Human Immunodeficiency Virus Market Segment Analysis - By Diagnosing Tests

The Human Immunodeficiency Virus Market based on the diagnosing type can be further segmented into Hospitals, Research and laboratories, and Blood banks, etc. The Research and Diagnostic segment held the largest share in 2021 owing to the factors such as expanding cognizance among people around the world as the prevalence of AIDS cases is upsurging as an outcome of which people are not waiting for symptoms to show up and diagnosing themselves beforehand.

Moreover, the research and diagnostic segment are estimated to be the fastest-growing segment with a CAGR of 9.7% over the forecast period 2022-2027. This growth is owing to swell in initiatives taken by the government to spread responsiveness about human immunodeficiency viruses such as TV advertisements, steps toward giving children suitable sexual education in schools, escalating streams of hard cash into the research and development field. Additionally, WHO has been a proactive player in controlling the disease escalation, as it has been a co-sponsor of the Joint United Nations Program on AIDS. Moreover, the strategic direction has “information for focused action” as one of the primary steps which enforced the use of diagnosis, while putting equal importance to the other “innovation for acceleration” which tends to allow for future opportunities.

Human Immunodeficieny Virus Market Segment Analysis - By cGeography

The Human Immunodeficiency Virus based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held the largest share with 36% of the overall market in 2021. The growth in this segment is owing to the factors such as the Vast section of the North American population being literate, escalation in consciousness among people about sexually transmitted diseases, extensive focus on research and development of new-fangled drugs due to the prevalent presence of a leading player like Pfizer in medical sciences field, affluent GDPs drive government to invest more riches in drug discovery field, presence of research and diagnostic laboratories with world-class infrastructure. Moreover, the USA has been a key supplier to the most afflicted African region, which currently has a caseload of close to 25.5 million.

However, the Asia-Pacific segment is estimated to be the the forecast period 2022-2027. The growth is owing to factors incrementing figures of AIDS cases due to nonexistence of knowledge about sources of sexually transmitted diseases (SITs), enlarging coupled inhabitants, extravagant concentration upon enhancement of health infrastructure as GDPs of developing nations like India, China, Vietnam, Indonesia, and Bangladesh is on rising.

Human Immunodeficieny Virus Market Drivers

A bulge in activities enhancing cognizance among people is Projected to Drive Market Growth

Humanity is living in the 21st century and topics related to the biology of a person are no longer considered taboo. Open debates about sexually transmitted diseases such as AIDS are being held every now and then. Nowadays government, celebrities acquiescently indulge themselves in events and programs that are related to spreading responsiveness among people through advertisements and shows. Concepts of sexual education are being introduced in school curriculum and books. Therefore, consciousness among people is enlarging and eventually driving the diagnostic market.

A multitudinous stream of hard cash into research and development is Expected to Boost Product Demand

Post globalization economies of nations around the globe have amended and grown-up to an enchanted scale. Especially, developing countries like China and India are asserting their dominance at the world stage due to luring economies. Therefore, with an escalation in affluence, these nations are giving supplementary prominence to healthcare infrastructures such as world-class hospitals, laboratories, and institutions. In budget 2021-2022, the Indian government allocated around $2.2 billion which is 137% additional than the preceding year’s expenditure.

Human Immunodeficieny Virus Market Challenges

Hampered supply chain across the world is Anticipated to Hamper Market Growth

COVID-19 fallouts are not concealed to anyone. Widescale lockdowns, travel, and trade restrictions have made it problematic for suppliers around the world to export essential raw materials such as APIs (= active pharmaceutical drugs), drugs such as antiretrovirals, and other apparatuses. China is a major API fabricator of the world but the outbreak of SARS-Cov-2 in China hampered the global supply chain and ensured an impediment to numerous research processes, diagnostic treatments, and therapies. Numerous impacts of this tragedy are yet to come and are estimated to further hamper the progress of the HIV market. Additionally, WHO has formulated a five-step supply plan for helping the afflicted countries, of the five around 3 steps within the process were severely hampered, which in turn made them reconsider their prior commitments.

Human Immunodeficiency Virus Market Competitive Landscape:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in this market. Human Immunodeficiency Virus top 10 companies include:

1. Pfizer Inc.
2. Abbott
3. Bristol-Myers Squibb Company
4. Sanofi
5. GlaxoSmithKline plc.
6. Novartis AG
7. Gilead Sciences, Inc.
8. ViiV Healthcare
9. Cipla
10. Merck

Partnerships/Product Launches:

• On November 16, 2021, the World health organization (WHO) has revealed a new-fangled toolkit to help countries around the world to ramp up their efforts in espousing guidelines suggested by WHO back in 2019 to adopt a standard testing strategy for HIV diagnoses. For example, in the WHO African Region, compliance to HIV testing strategies increased from 8% in 2014 to 71% in 2021. Fifteen low- and middle-income countries have already begun using elements of the toolkit to improve testing.
• On November 10, 2021, Experimental Capsid Inhibitor Lenacapavir has been receiving nods all around for the treatment of HIV. These are important trials that advance understanding of the strengths and weaknesses of lenacapavir. The potency and remarkable semi-annual dosing of the subcutaneous formulation will likely offset the relatively lower barrier to resistance (compared to bictegravir and dolutegravir, for example) and injection-site reactions.
• On January 9, 2021, Excitement is also mounting for the very real possibility that a long-acting injectable to prevent HIV will soon be approved. As 2020 came to a close, the FDA granted breakthrough designation to ViiV Healthcare’s cabotegravir—one of the two drugs in HIV treatment candidate Cabenuva—for the prevention of HIV. Cabotegravir is administered once every 2 months. The treatment has so far effectively prevented HIV infection in transgender women and gay men.

Relevant Links: